Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas
Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was p...
Gespeichert in:
| Veröffentlicht in: | The Journal of pathology 1999-05, Vol.188 (1), p.51-55 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 51 |
| container_title | The Journal of pathology |
| container_volume | 188 |
| creator | de Krijger, Ronald R. van der Harst, Erwin van der Ham, Frieda Stijnen, Theo Dinjens, Winand N. M. Koper, Jan W. Bruining, Hajo A. Lamberts, Steven W. J. Bosman, Fred T. |
| description | Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was performed with antibodies to the tumour suppressor gene product p53 and the proto‐oncogene products bcl‐2 and c‐erbB‐2, using the avidin–biotin complex method. Malignant phaeochromocytomas showed a statistically significant higher frequency of p53 (p=0·042) and bcl‐2 (p=0·037) protein expression than their benign counterparts. The combination of both markers showed an even higher significance (p=0·004), to which both markers contributed equally. Overexpression of c‐erbB‐2 was associated with the occurrence of familial phaeochromocytomas (p=0·001), but no difference was found between benign and malignant cases. In conclusion, p53, bcl‐2, and c‐erbB‐2 all appear to be involved in the pathogenesis of a proportion of phaeochromocytomas. Immunoreactivity to p53 and bcl‐2 proteins may help to predict the clinical behaviour of phaeochromocytomas. Copyright © 1999 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69941447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69941447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5340-dfad4c5dc1eda0bd43d0a06b9d0b5153e33c5c5713f73ba2506667192c8e0b423</originalsourceid><addsrcrecordid>eNqFkeFr1DAYh4so7pz-C9IPIhssZ96kaZpTlFvV7WR4Y94Y-OUlTVNX7TVn0tPdf2-PnlNQ2KfQ8PThR54oegN0DJSyFwefZvnsEKhKicpUegBKKSoOIcsm8ErAZDKdvSXn08UpB_qaj-k4n79k5OJeNLr953406k2M8ATkXvQohK-UUqWEeBjtAeUqg4SOostz7760LnS1iX_oZm1jV8UrwY_iwjSEHcW6LWNDrC-OCYtX3nW2bmN7s_I2hNq1cf-1utbWmWvvls5sOrfU4XH0oNJNsE925350-f7dIj8lZ_OTWT49I0bwhJKy0mViRGnAlpoWZcJLqmlaqJIWAgS3nBthhAReSV5oJmiaphIUM5mlRcL4fvR88PbDvq9t6HBZB2ObRrfWrQOmSiWQJPJOECQTQia8B68G0HgXgrcVrny91H6DQHGbBnGbBrfPjNtnxiEN9mkQUABinwZ3aZAjxXyODC9689PdhHWxtOVf3qFFDzzbAToY3VRet6YOfzgpBXDRY58H7Gfd2M0_8-5Y9_9xv696ORnkdejsza1c-2-YSi4FXn08QRDH6Qe2WGDGfwF7OcTr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17255743</pqid></control><display><type>article</type><title>Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>de Krijger, Ronald R. ; van der Harst, Erwin ; van der Ham, Frieda ; Stijnen, Theo ; Dinjens, Winand N. M. ; Koper, Jan W. ; Bruining, Hajo A. ; Lamberts, Steven W. J. ; Bosman, Fred T.</creator><creatorcontrib>de Krijger, Ronald R. ; van der Harst, Erwin ; van der Ham, Frieda ; Stijnen, Theo ; Dinjens, Winand N. M. ; Koper, Jan W. ; Bruining, Hajo A. ; Lamberts, Steven W. J. ; Bosman, Fred T.</creatorcontrib><description>Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was performed with antibodies to the tumour suppressor gene product p53 and the proto‐oncogene products bcl‐2 and c‐erbB‐2, using the avidin–biotin complex method. Malignant phaeochromocytomas showed a statistically significant higher frequency of p53 (p=0·042) and bcl‐2 (p=0·037) protein expression than their benign counterparts. The combination of both markers showed an even higher significance (p=0·004), to which both markers contributed equally. Overexpression of c‐erbB‐2 was associated with the occurrence of familial phaeochromocytomas (p=0·001), but no difference was found between benign and malignant cases. In conclusion, p53, bcl‐2, and c‐erbB‐2 all appear to be involved in the pathogenesis of a proportion of phaeochromocytomas. Immunoreactivity to p53 and bcl‐2 proteins may help to predict the clinical behaviour of phaeochromocytomas. Copyright © 1999 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R</identifier><identifier>PMID: 10398140</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adrenal Gland Neoplasms - chemistry ; Adrenal Gland Neoplasms - genetics ; Adrenal Gland Neoplasms - pathology ; Adrenals. Adrenal axis. Renin-angiotensin system (diseases) ; Adult ; bcl-2 ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; c-erbB-2 ; Endocrinopathies ; Female ; Humans ; Immunohistochemistry ; Male ; Medical sciences ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; oncogene ; p53 ; phaeochromocytoma ; Pheochromocytoma - chemistry ; Pheochromocytoma - genetics ; Pheochromocytoma - pathology ; Prognosis ; Proto-Oncogene Proteins c-bcl-2 - analysis ; Receptor, ErbB-2 - analysis ; Statistics, Nonparametric ; Tumor Suppressor Protein p53 - analysis</subject><ispartof>The Journal of pathology, 1999-05, Vol.188 (1), p.51-55</ispartof><rights>Copyright © 1999 John Wiley & Sons, Ltd.</rights><rights>1999 INIST-CNRS</rights><rights>Copyright 1999 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5340-dfad4c5dc1eda0bd43d0a06b9d0b5153e33c5c5713f73ba2506667192c8e0b423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291096-9896%28199905%29188%3A1%3C51%3A%3AAID-PATH310%3E3.0.CO%3B2-R$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291096-9896%28199905%29188%3A1%3C51%3A%3AAID-PATH310%3E3.0.CO%3B2-R$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1775135$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10398140$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Krijger, Ronald R.</creatorcontrib><creatorcontrib>van der Harst, Erwin</creatorcontrib><creatorcontrib>van der Ham, Frieda</creatorcontrib><creatorcontrib>Stijnen, Theo</creatorcontrib><creatorcontrib>Dinjens, Winand N. M.</creatorcontrib><creatorcontrib>Koper, Jan W.</creatorcontrib><creatorcontrib>Bruining, Hajo A.</creatorcontrib><creatorcontrib>Lamberts, Steven W. J.</creatorcontrib><creatorcontrib>Bosman, Fred T.</creatorcontrib><title>Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was performed with antibodies to the tumour suppressor gene product p53 and the proto‐oncogene products bcl‐2 and c‐erbB‐2, using the avidin–biotin complex method. Malignant phaeochromocytomas showed a statistically significant higher frequency of p53 (p=0·042) and bcl‐2 (p=0·037) protein expression than their benign counterparts. The combination of both markers showed an even higher significance (p=0·004), to which both markers contributed equally. Overexpression of c‐erbB‐2 was associated with the occurrence of familial phaeochromocytomas (p=0·001), but no difference was found between benign and malignant cases. In conclusion, p53, bcl‐2, and c‐erbB‐2 all appear to be involved in the pathogenesis of a proportion of phaeochromocytomas. Immunoreactivity to p53 and bcl‐2 proteins may help to predict the clinical behaviour of phaeochromocytomas. Copyright © 1999 John Wiley & Sons, Ltd.</description><subject>Adrenal Gland Neoplasms - chemistry</subject><subject>Adrenal Gland Neoplasms - genetics</subject><subject>Adrenal Gland Neoplasms - pathology</subject><subject>Adrenals. Adrenal axis. Renin-angiotensin system (diseases)</subject><subject>Adult</subject><subject>bcl-2</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>c-erbB-2</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>oncogene</subject><subject>p53</subject><subject>phaeochromocytoma</subject><subject>Pheochromocytoma - chemistry</subject><subject>Pheochromocytoma - genetics</subject><subject>Pheochromocytoma - pathology</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - analysis</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Statistics, Nonparametric</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkeFr1DAYh4so7pz-C9IPIhssZ96kaZpTlFvV7WR4Y94Y-OUlTVNX7TVn0tPdf2-PnlNQ2KfQ8PThR54oegN0DJSyFwefZvnsEKhKicpUegBKKSoOIcsm8ErAZDKdvSXn08UpB_qaj-k4n79k5OJeNLr953406k2M8ATkXvQohK-UUqWEeBjtAeUqg4SOostz7760LnS1iX_oZm1jV8UrwY_iwjSEHcW6LWNDrC-OCYtX3nW2bmN7s_I2hNq1cf-1utbWmWvvls5sOrfU4XH0oNJNsE925350-f7dIj8lZ_OTWT49I0bwhJKy0mViRGnAlpoWZcJLqmlaqJIWAgS3nBthhAReSV5oJmiaphIUM5mlRcL4fvR88PbDvq9t6HBZB2ObRrfWrQOmSiWQJPJOECQTQia8B68G0HgXgrcVrny91H6DQHGbBnGbBrfPjNtnxiEN9mkQUABinwZ3aZAjxXyODC9689PdhHWxtOVf3qFFDzzbAToY3VRet6YOfzgpBXDRY58H7Gfd2M0_8-5Y9_9xv696ORnkdejsza1c-2-YSi4FXn08QRDH6Qe2WGDGfwF7OcTr</recordid><startdate>199905</startdate><enddate>199905</enddate><creator>de Krijger, Ronald R.</creator><creator>van der Harst, Erwin</creator><creator>van der Ham, Frieda</creator><creator>Stijnen, Theo</creator><creator>Dinjens, Winand N. M.</creator><creator>Koper, Jan W.</creator><creator>Bruining, Hajo A.</creator><creator>Lamberts, Steven W. J.</creator><creator>Bosman, Fred T.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199905</creationdate><title>Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas</title><author>de Krijger, Ronald R. ; van der Harst, Erwin ; van der Ham, Frieda ; Stijnen, Theo ; Dinjens, Winand N. M. ; Koper, Jan W. ; Bruining, Hajo A. ; Lamberts, Steven W. J. ; Bosman, Fred T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5340-dfad4c5dc1eda0bd43d0a06b9d0b5153e33c5c5713f73ba2506667192c8e0b423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adrenal Gland Neoplasms - chemistry</topic><topic>Adrenal Gland Neoplasms - genetics</topic><topic>Adrenal Gland Neoplasms - pathology</topic><topic>Adrenals. Adrenal axis. Renin-angiotensin system (diseases)</topic><topic>Adult</topic><topic>bcl-2</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>c-erbB-2</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>oncogene</topic><topic>p53</topic><topic>phaeochromocytoma</topic><topic>Pheochromocytoma - chemistry</topic><topic>Pheochromocytoma - genetics</topic><topic>Pheochromocytoma - pathology</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - analysis</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Statistics, Nonparametric</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Krijger, Ronald R.</creatorcontrib><creatorcontrib>van der Harst, Erwin</creatorcontrib><creatorcontrib>van der Ham, Frieda</creatorcontrib><creatorcontrib>Stijnen, Theo</creatorcontrib><creatorcontrib>Dinjens, Winand N. M.</creatorcontrib><creatorcontrib>Koper, Jan W.</creatorcontrib><creatorcontrib>Bruining, Hajo A.</creatorcontrib><creatorcontrib>Lamberts, Steven W. J.</creatorcontrib><creatorcontrib>Bosman, Fred T.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Krijger, Ronald R.</au><au>van der Harst, Erwin</au><au>van der Ham, Frieda</au><au>Stijnen, Theo</au><au>Dinjens, Winand N. M.</au><au>Koper, Jan W.</au><au>Bruining, Hajo A.</au><au>Lamberts, Steven W. J.</au><au>Bosman, Fred T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>1999-05</date><risdate>1999</risdate><volume>188</volume><issue>1</issue><spage>51</spage><epage>55</epage><pages>51-55</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was performed with antibodies to the tumour suppressor gene product p53 and the proto‐oncogene products bcl‐2 and c‐erbB‐2, using the avidin–biotin complex method. Malignant phaeochromocytomas showed a statistically significant higher frequency of p53 (p=0·042) and bcl‐2 (p=0·037) protein expression than their benign counterparts. The combination of both markers showed an even higher significance (p=0·004), to which both markers contributed equally. Overexpression of c‐erbB‐2 was associated with the occurrence of familial phaeochromocytomas (p=0·001), but no difference was found between benign and malignant cases. In conclusion, p53, bcl‐2, and c‐erbB‐2 all appear to be involved in the pathogenesis of a proportion of phaeochromocytomas. Immunoreactivity to p53 and bcl‐2 proteins may help to predict the clinical behaviour of phaeochromocytomas. Copyright © 1999 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>10398140</pmid><doi>10.1002/(SICI)1096-9896(199905)188:1<51::AID-PATH310>3.0.CO;2-R</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3417 |
| ispartof | The Journal of pathology, 1999-05, Vol.188 (1), p.51-55 |
| issn | 0022-3417 1096-9896 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69941447 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adrenal Gland Neoplasms - chemistry Adrenal Gland Neoplasms - genetics Adrenal Gland Neoplasms - pathology Adrenals. Adrenal axis. Renin-angiotensin system (diseases) Adult bcl-2 Biological and medical sciences Biomarkers, Tumor - analysis c-erbB-2 Endocrinopathies Female Humans Immunohistochemistry Male Medical sciences Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms oncogene p53 phaeochromocytoma Pheochromocytoma - chemistry Pheochromocytoma - genetics Pheochromocytoma - pathology Prognosis Proto-Oncogene Proteins c-bcl-2 - analysis Receptor, ErbB-2 - analysis Statistics, Nonparametric Tumor Suppressor Protein p53 - analysis |
| title | Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A04%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20p53,%20bcl-2,%20and%20c-erbB-2%20protein%20expression%20in%20phaeochromocytomas&rft.jtitle=The%20Journal%20of%20pathology&rft.au=de%20Krijger,%20Ronald%20R.&rft.date=1999-05&rft.volume=188&rft.issue=1&rft.spage=51&rft.epage=55&rft.pages=51-55&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/(SICI)1096-9896(199905)188:1%3C51::AID-PATH310%3E3.0.CO;2-R&rft_dat=%3Cproquest_cross%3E69941447%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17255743&rft_id=info:pmid/10398140&rfr_iscdi=true |